A Novel Single Nucleotide Polymorphism of the Cyclooxygenase-2 Gene Associated with Breast Cancer

Clinical Oncology

Volumn 21, Issue 4, 2009, Pages 302-305

  Li, F ^a   Ren, G S ^a   Li, H Y ^a   Wang, X Y ^a   Chen, L ^a   Li, J ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; cyclooxygenase 2 gene; genetics; polymorphism

Indexed keywords

ALANINE; CYCLOOXYGENASE 2; CYTOSINE; ESTROGEN RECEPTOR; GUANINE; NUCLEOTIDE; PROGESTERONE RECEPTOR; PROLINE;

ARTICLE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

BREAST NEOPLASMS; CONFIDENCE INTERVALS; CYCLOOXYGENASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MUTATION; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 62749190612     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.12.005     Document Type: Article

References (12)

1. Smith W.L., Garavito R.M., and De Witt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
2. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56 (2004) 387-437
3. Soslow R.A., Dannenberg A.J., Rush D., et al. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
4. Denkert C., Winzer K.J., and Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 4 (2004) 428-433
5. Pereg D., and Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258 (2005) 115-123
6. Arun B., and Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31 (2004) 22-29
7. Bundred N.J., and Barnes N.L. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer 93 Suppl 1 (2005) 10-15
8. Nakayama T., Soma M., Takahashi Y., Rehemudula D., Kanmatsuse K., and Furuya K. Functional deletion mutation of the intron 9 of the type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 86 (2000) 841-845
9. Langsenlehner U., Babak Y.B., Tanja E., et al. The cyclooxygenase-2 (PTGS2) 8473T > C polymorphism is associated with breast cancer risk. Clin Cancer Res 12 (2006) 1392-1394
10. Moraitis D., Du B., De Lorenzo M.S., et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65 (2005) 664-670
11. Wulfing P., Diallo R., Muller C., et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129 (2003) 375-382
12. Johnson M.L., and Seidman A.D. Emerging targeted therapies for breast cancer. Oncology (Williston Park) 19 (2005) 611-618